Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

By Edward S Kim, V. Hirsh, T. Mok, M. Socinski, R. Gervais, Yi-long Wu, Long-yun Li, C. Watkins, M. Sellers, E. Lowe and 8 more. The Lancet, 2008

1,292 citations recorded by the source corpus.

Subfields: Oncology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/f6a2c5d53638b0923f870f6fb6d3c092b74b84b4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. William Pao
2. Sanjay Gupta

In Pulmonary and Respiratory Medicine

1. B. Hughes
2. B. Chan
3. William Pao
4. S. Lippman
5. Christine Lovly
6. Z. Du

Citations in the corpus

• Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer (2015, neutral): “Unknown or not reported 10 (7) 6 (4) 16 (6)”
• Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. (2015, methodology): “The INTEREST study was a multinational phase III randomised trial that compared gefitinib to docetaxel in unselected second-line patients (Table 1) (31).”
• The BATTLE Trial: Personalizing Therapy for Lung Cancer (2011, result): “Our overall response rate of 4% is reflective of a heavily pretreated NSCLC population and consistent with other published studies in this population (5, 9, 14).”
• American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. (2009, background): “For example, there was no difference in OS in the small subgroup of EGFR mutation–positive patients randomly assigned between gefitinib and docetaxel in the INTEREST study.(33)”